Melissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.
Melissa M. Hardesty, MD
Articles by Melissa M. Hardesty, MD
Melissa M. Hardesty, MD, discusses the challenges faced within the community setting in regard to the treatment landscape for advanced ovarian cancer.
